The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Obesity, Cardiorenal Comorbidities, and Risk of Hospitalization in Patients With Heart Failure With Preserved Ejection Fraction
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Hypertension, CKD and blood volume expansion are the three features that best distinguish obesity-related HFpEF from asymptomatic individuals with obesity but no HF.
“Indeed, hypertension, CKD and BV expansion are the three features that best distinguish obesity-related HFpEF from asymptomatic individuals with obesity but no HF9.”
From Effects of tirzepatide on circulatory overload and end-organ damage in heart failure with preserved ejection fraction and obesity: a secondary analysis of the SUMMIT trial (2025) · cites this paper as [9]
Tables 1 and 2 show more hypertension and CKD in the HFpEF group than in BMI-matched controls, and the Discussion reports greater volume expansion. The paper does not identify these as the three features that best distinguish the groups; it also reports differences in other cardiometabolic comorbidities. (LLM, conf=0.88)
Experimental — accuracy not yet measuredObesity-related HFpEF is the most common phenotype of this disorder, and its emergence is causally related to the growing burden of cardiovascular-kidney-metabolic disorders observed worldwide.
“Obesity-related HFpEF is the most common phenotype of this disorder3,9, and its emergence is causally related to the growing burden of cardiovascular–kidney–metabolic disorders observed worldwide4.”
From Effects of tirzepatide on circulatory overload and end-organ damage in heart failure with preserved ejection fraction and obesity: a secondary analysis of the SUMMIT trial (2025) · cites this paper as [9]
The Results report obesity in 57.8% of patients with HFpEF who had BMI data, supporting that obesity-related HFpEF was common in this US dataset. The paper does not establish that it is the most common phenotype worldwide. The causal claim is attached to a different citation in the citing sentence and is not judged here. (LLM, conf=0.82)
Experimental — accuracy not yet measuredVolume expansion, CKD and greater burden of hypertension best distinguish individuals with obesity-related HFpEF from age, sex and BMI-matched patients with obesity but no HF.
“Indeed, volume expansion, CKD and greater burden of hypertension best distinguish individuals from obesity-related HFpEF from age, sex and BMI-matched patients with obesity but no HF9.”
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Dapagliflozin in Patients with Chronic Kidney Disease
Heerspink, H. J. L., Stefánsson, B. V., Correa-Rotter, R., Chertow, G. M., Greene, T., Hou, F.-F., Mann, J. F. E., McMurray, J. J. V., Lindberg, M., Rossing, P., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2024816 · Cited by 5,618
A Novel Paradigm for Heart Failure With Preserved Ejection Fraction
Paulus, W. J., & Tschöpe, C. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.02.092 · Cited by 3,564
Ross, R., Neeland, I. J., Yamashita, S., Shai, I., Seidell, J., Magni, P., Santos, R. D., Arsenault, B., Cuevas, A., Hu, F. B., et al. (2020) · Nature Reviews Endocrinology · doi:10.1038/s41574-019-0310-7 · Cited by 1,966
Cardiovascular events with finerenone in kidney disease and type 2 diabetes
Pitt, B., Filippatos, G., Agarwal, R., Anker, S. D., Bakris, G. L., Rossing, P., Joseph, A., Kolkhof, P., Nowack, C., Schloemer, P., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2110956 · Cited by 1,814
Borlaug, B. A., Jensen, M. D., Kitzman, D. W., Lam, C. S. P., Obokata, M., & Rider, O. J. (2023) · Cardiovascular Research · doi:10.1093/cvr/cvac120 · Cited by 450
Self-citationKoepp, K. E., Obokata, M., Reddy, Y. N. V., Olson, T. P., & Borlaug, B. A. (2020) · JACC Heart Failure · doi:10.1016/j.jchf.2020.04.016 · Cited by 269
Self-citationReddy, Y. N. V., Rikhi, A., Obokata, M., Shah, S. J., Lewis, G. D., AbouEzzedine, O. F., Dunlay, S., McNulty, S., Chakraborty, H., Stevenson, L. W., et al. (2020) · European Journal of Heart Failure · doi:10.1002/ejhf.1788 · Cited by 243
Self-citationPacker, M., Lam, C. S. P., Lund, L. H., Maurer, M. S., & Borlaug, B. A. (2020) · European Journal of Heart Failure · doi:10.1002/ejhf.1902 · Cited by 185
Self-citationObesity, venous capacitance, and venous compliance in heart failure with preserved ejection fraction
Sorimachi, H., Burkhoff, D., Verbrugge, F. H., Omote, K., Obokata, M., Reddy, Y. N. V., Takahashi, N., Sunagawa, K., & Borlaug, B. A. (2021) · European Journal of Heart Failure · doi:10.1002/ejhf.2254 · Cited by 124
Self-citation
Flagged first, then by citations
Research works printed but not linked: 21
- Blüher, 2019, Obesity: global epidemiology and pathogenesis, Nat Rev Endocrinol, 15, 288, 10.1038/s41574-019-0176-8 · DOI · Paper page
- Dunlay, 2017, Epidemiology of heart failure with preserved ejection fraction, Nat Rev Cardiol, 14, 591, 10.1038/nrcardio.2017.65 · DOI
- Tadic, 2019, Obesity and heart failure with preserved ejection fraction: a paradox or something else?, Heart Fail Rev, 24, 379, 10.1007/s10741-018-09766-x · DOI
- Obokata, 2017, Evidence supporting the existence of a distinct obese phenotype of heart failure with preserved ejection fraction, Circulation, 136, 6, 10.1161/CIRCULATIONAHA.116.026807 · DOI · Paper page
- Sorimachi, 2021, Pathophysiologic importance of visceral adipose tissue in women with heart failure and preserved ejection fraction, Eur Heart J, 42, 1595, 10.1093/eurheartj/ehaa823 · DOI · Paper page
- Haass, 2011, Body mass index and adverse cardiovascular outcomes in heart failure patients with preserved ejection fraction: results from the Irbesartan in Heart Failure with Preserved Ejection Fraction (I-PRESERVE) trial, Circ Heart Fail, 4, 324, 10.1161/CIRCHEARTFAILURE.110.959890 · DOI · Paper page
- Mandviwala, 2020, Obesity and the paradox of mortality and heart failure hospitalization in heart failure with preserved ejection fraction, Int J Obes (Lond), 44, 1561, 10.1038/s41366-020-0563-1 · DOI
- 2016, Guidelines for good pharmacoepidemiology practice (GPP), Pharmacoepidemiol Drug Saf, 25, 2, 10.1002/pds.3891 · DOI
- Adamson, 2022, Dapagliflozin for heart failure according to body mass index: the DELIVER trial, Eur Heart J, 43, 4406, 10.1093/eurheartj/ehac481 · DOI
- Redfield, 2023, Heart failure with preserved ejection fraction: a review, JAMA, 329, 827, 10.1001/jama.2023.2020 · DOI · Paper page
- Vaishnav, 2022, Under-enrollment of obese heart failure with preserved ejection fraction patients in major HFpEF clinical trials, J Card Fail, 28, 723, 10.1016/j.cardfail.2021.12.007 · DOI
- Pandey, 2018, Physical activity, fitness, and obesity in heart failure with preserved ejection fraction, JACC Heart Fail, 6, 975, 10.1016/j.jchf.2018.09.006 · DOI
- Borlaug, 2019, The role of the pericardium in heart failure: implications for pathophysiology and treatment, JACC Heart Fail, 7, 574, 10.1016/j.jchf.2019.03.021 · DOI
- Ng, 2021, Diabesity: the combined burden of obesity and diabetes on heart disease and the role of imaging, Nat Rev Cardiol, 18, 291, 10.1038/s41569-020-00465-5 · DOI
- Rayner, 2020, Myocardial energetics in obesity: enhanced ATP delivery through creatine kinase with blunted stress response, Circulation, 141, 1152, 10.1161/CIRCULATIONAHA.119.042770 · DOI
- Solomon, 2019, Angiotensin-neprilysin inhibition in heart failure with preserved ejection fraction, N Engl J Med, 381, 1609, 10.1056/NEJMoa1908655 · DOI · Paper page
- 2000, Obesity: preventing and managing the global epidemic. Report of a WHO consultation, World Health Organ Tech Rep Ser, 894i-xii, 1
- Carbone, 2018, Obesity and mortality risk in heart failure: when adipose tissue distribution matters, Eur J Heart Fail, 20, 1278, 10.1002/ejhf.1279 · DOI
- Lavie, 2017, Adipose composition and heart failure prognosis: paradox or not?, J Am Coll Cardiol, 70, 2750, 10.1016/j.jacc.2017.10.017 · DOI
- Tsujimoto T, Kajio H. Abdominal obesity is associated with an increased risk of all-cause mortality in patients with HFpEF. J Am Coll Cardiol. 2017;70(22):2739-2749. Published correction appears in J Am Coll Cardiol. 2018;71(9):1059. · DOI
- Carbone, 2020, Disparate effects of obesity on survival and hospitalizations in heart failure with preserved ejection fraction, Int J Obes (Lond), 44, 1543, 10.1038/s41366-020-0579-6 · DOI
Cited by
Sorted by citations
Borlaug, B. A., Kitzman, D. W., Davies, M. J., Rasmussen, S., Barros, E., Butler, J., Einfeldt, M. N., Hovingh, G. K., Møller, D. V., Petrie, M. C., et al. (2023) · Nature Medicine · doi:10.1038/s41591-023-02526-x · Cited by 215
Self-citationBorlaug, B. A., Zile, M. R., Kramer, C. M., Baum, S. J., Hurt, K., Litwin, S. E., Murakami, M., Ou, Y., Upadhyay, N., & Packer, M. (2025) · Nature Medicine · doi:10.1038/s41591-024-03374-z · Cited by 166
Self-citationKosiborod, M. N., Verma, S., Borlaug, B. A., Butler, J., Davies, M. J., Jon Jensen, T., Rasmussen, S., Erlang Marstrand, P., Petrie, M. C., Shah, S. J., et al. (2024) · Circulation · doi:10.1161/circulationaha.123.067505 · Cited by 104
Self-citationGLP-1 receptor agonist-based therapies and cardiovascular risk: a review of mechanisms
Mullur, N., Morissette, A., Morrow, N. M., & Mulvihill, E. E. (2024) · Journal of Endocrinology · doi:10.1530/joe-24-0046 · Cited by 51
Packer, M., Zile, M. R., Kramer, C. M., Murakami, M., Ou, Y., & Borlaug, B. A. (2025) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2025.03.009 · Cited by 49
Self-citationVerma, R., Dhingra, N. K., & Connelly, K. A. (2024) · Current Opinion in Cardiology · doi:10.1097/hco.0000000000001113 · Cited by 24
Metadata
- Authors
- Morgen, C. S., Haase, C. L., Oral, T. K., Schnecke, V., Varbo, A., & Borlaug, B. A.
- Venue
- Mayo Clinic Proceedings
- Publisher
- Elsevier BV
- Published
- 2023-10
- Volume
- 98
- Issue
- 10
- Pages
- 1458-1468
- ISSN
- 0025-6196
- Cited by
- 32
- References
- 9
- Language
- en
- Licence
- Funders
- Novo Nordisk
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
